Evommune, Inc.
EVMN
NYSE·Healthcare·Biotechnology·Mkt cap $445.3M
$12.27
▲ +2.25%
P/E
-4.34
Mkt Cap
$445.3M
52-Wk Range
$10.47–$33.20
52-Week Range
$10.47 - $33.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 39.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Targeted mechanism of action addressing key disease drivers
- Multi-indication pipeline reducing development risk
- Early-stage position allowing patent protection and exclusivity
- Experienced biotech leadership team in Palo Alto innovation hub
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Advancement of EVO756 through clinical development phases
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-39.2% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying EVMN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 16, 2026
AUG 6, 2026
Reported EPS of -$0.89 vs -$0.66 consensus (-33.9% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-33.9%
Revenue trend · last 8Q
—
—
-57%
—
—
—
-100%
—
Q2 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$3.0M
$0
$10.0M
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
5 analysts · 60% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
60%
Hold
40%
Sell
0%
Median Price Target
—
Latest: Needham · Aug 26, 2026
vs Industry
How EVMN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related